• Explore /
  • Poster
  • / A phase II trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma.

A phase II trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma.

Abstract Poster

Authors

Kanwal Raghav

Kanwal Pratap Singh Raghav

The University of Texas MD Anderson Cancer Center, Houston, TX

Kanwal Pratap Singh Raghav , Michael J. Overman , Suyu Liu , Anneleis Willett , Richard Eldon Royal , Anais Malpica , Christopher Scally , Ignacio Ivan Wistuba , Andrew Futreal , Armeen Mahvash , Cindy Yun , Shannon Dervin , Edward Francis Mckenna Jr., Katja Schulze , Patrick Hwu , James C. Yao , Scott Kopetz , Gauri Rajani Varadhachary , Daniel M. Halperin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Mesothelioma

Clinical Trial Registration Number

NCT03074513

Citation

J Clin Oncol 38: 2020 (suppl; abstr 9013)

DOI

10.1200/JCO.2020.38.15_suppl.9013

Abstract #

9013

Poster Bd #

206

Abstract Disclosures

Similar Posters

First Author: Kazuomi Ueshima

First Author: Lili Mao

First Author: Aaron Scott Mansfield

First Author: Dean Anthony Fennell